• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

混合型肝细胞癌-胆管细胞癌具有祖细胞特征,并激活了 Wnt 和 TGFβ 信号通路。

Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.

机构信息

INSERM, UMR991, Université de Rennes 1, Liver Metabolisms and Cancer Rennes, France.

出版信息

Carcinogenesis. 2012 Sep;33(9):1791-6. doi: 10.1093/carcin/bgs208. Epub 2012 Jun 13.

DOI:10.1093/carcin/bgs208
PMID:22696594
Abstract

Intrahepatic malignant tumours include hepatocellular carcinomas (HCC), cholangiocarcinomas (CC) and combined hepatocholangiocarcinomas (cHCC-CC), a group of rare and poorly characterized tumours that exhibit both biliary and hepatocytic differentiation. The aim of the study was to characterize the molecular pathways specifically associated with cHCC-CC pathogenesis. We performed a genome-wide transcriptional analysis of 20 histologically defined cHCC-CC and compared them with a series of typical HCC and of CC. Data were analysed by gene set enrichment and integrative genomics and results were further validated in situ by tissue microarray using an independent series of 152 tumours. We report that cHCC-CC exhibit stem/progenitor features, a down-regulation of the hepatocyte differentiation program and a commitment to the biliary lineage. TGFβ and Wnt/β-catenin were identified as the two major signalling pathways activated in cHCC-CC. A β-catenin signature distinct from that observed in well-differentiated HCC with mutant β-catenin was found in cHCC-CC. This signature was associated with microenvironment remodelling and TGFβ activation. Furthermore, integrative genomics revealed that cHCC-CC share characteristics of poorly differentiated HCC with stem cell traits and poor prognosis. The common traits displayed by CC, cHCC-CC and some HCC suggest that these tumours could originate from stem/progenitor cell(s) and raised the hypothesis of a potential continuum between intrahepatic CC, cHCC-CC and poorly differentiated HCC.

摘要

肝内恶性肿瘤包括肝细胞癌 (HCC)、胆管细胞癌 (CC) 和混合性肝内胆管细胞癌 (cHCC-CC),它们是一组罕见且特征不明显的肿瘤,具有胆管和肝细胞分化特征。本研究旨在描述与 cHCC-CC 发病机制相关的特定分子途径。我们对 20 例组织学明确的 cHCC-CC 进行了全基因组转录组分析,并将其与一系列典型的 HCC 和 CC 进行了比较。通过基因集富集和综合基因组学分析数据,并使用独立的 152 例肿瘤的组织微阵列进一步在原位验证结果。我们报告 cHCC-CC 表现出干细胞/祖细胞特征、肝细胞分化程序下调和向胆管谱系分化的趋势。TGFβ 和 Wnt/β-catenin 被确定为 cHCC-CC 中激活的两个主要信号通路。在 cHCC-CC 中发现了与突变型 β-catenin 在高分化 HCC 中观察到的不同的 β-catenin 特征。该特征与微环境重塑和 TGFβ 激活有关。此外,综合基因组学显示 cHCC-CC 具有具有干细胞特征和预后不良的低分化 HCC 的特征。CC、cHCC-CC 和一些 HCC 所共有的特征表明这些肿瘤可能起源于干细胞/祖细胞,并提出了肝内 CC、cHCC-CC 和低分化 HCC 之间可能存在潜在连续体的假说。

相似文献

1
Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.混合型肝细胞癌-胆管细胞癌具有祖细胞特征,并激活了 Wnt 和 TGFβ 信号通路。
Carcinogenesis. 2012 Sep;33(9):1791-6. doi: 10.1093/carcin/bgs208. Epub 2012 Jun 13.
2
Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.15例肝细胞癌合并胆管癌患者的临床病理特征
Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5.
3
A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.肝细胞癌中的纤维性基质成分表现出胆管癌样的基因表达特征和上皮-间充质转化。
Hepatology. 2012 Jun;55(6):1776-86. doi: 10.1002/hep.25570.
4
Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.肝细胞-胆管细胞癌合并症的临床与分子分析
J Hepatol. 2004 Aug;41(2):292-8. doi: 10.1016/j.jhep.2004.04.030.
5
Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.中国人肝细胞癌和胆管细胞癌合并癌与肝细胞癌和肝内胆管细胞癌的影像学特征比较。
Clin Radiol. 2019 May;74(5):407.e1-407.e10. doi: 10.1016/j.crad.2019.01.016. Epub 2019 Feb 21.
6
Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.多区域分析合并肝细胞癌-胆管细胞癌揭示了组织学多样性和分子克隆性。
Histopathology. 2024 Jan;84(2):402-408. doi: 10.1111/his.15081. Epub 2023 Oct 30.
7
Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma.肝癌合并胆管细胞癌患者的肝移植与切除术比较。
J Surg Oncol. 2013 May;107(6):608-12. doi: 10.1002/jso.23289. Epub 2013 Feb 5.
8
KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.KL-6粘蛋白是胆管癌一种有用的免疫组化标志物。
Oncol Rep. 2007 Apr;17(4):737-41.
9
Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.Wnt/β-连环蛋白信号通路有助于正常和致瘤性肝祖细胞的激活。
Cancer Res. 2008 Jun 1;68(11):4287-95. doi: 10.1158/0008-5472.CAN-07-6691.
10
Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.混合型肝细胞胆管细胞癌肿瘤:胆管细胞癌是一种独特的分子实体。
J Hepatol. 2017 May;66(5):952-961. doi: 10.1016/j.jhep.2017.01.010. Epub 2017 Jan 23.

引用本文的文献

1
Wnt Pathway-Targeted Therapy in Gastrointestinal Cancers: Integrating Benchside Insights with Bedside Applications.胃肠道癌症中的Wnt信号通路靶向治疗:将实验室见解与临床应用相结合
Cells. 2025 Jan 24;14(3):178. doi: 10.3390/cells14030178.
2
Combined hepatocellular cholangiocarcinoma: A clinicopathological update.肝细胞胆管癌合并症:临床病理进展
World J Hepatol. 2024 May 27;16(5):766-775. doi: 10.4254/wjh.v16.i5.766.
3
Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.双重检查点抑制剂在一名混合型肝细胞胆管癌患者中的疗效
BMJ Case Rep. 2024 May 2;17(5):e255003. doi: 10.1136/bcr-2023-255003.
4
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.肝细胞-胆管细胞癌:生物学、诊断与管理
Liver Cancer. 2023 Apr 24;13(1):6-28. doi: 10.1159/000530700. eCollection 2024 Feb.
5
Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma.肝细胞-胆管细胞癌联合病理与放射学诊断的最新进展
J Liver Cancer. 2021 Mar;21(1):12-24. doi: 10.17998/jlc.21.1.12. Epub 2021 Mar 31.
6
Radiofrequency ablation versus liver resection and liver transplantation for small combined hepatocellular-cholangiocarcinoma stratified by tumor size.根据肿瘤大小分层的小肝细胞-胆管癌射频消融与肝切除及肝移植的比较
Langenbecks Arch Surg. 2023 Mar 15;408(1):119. doi: 10.1007/s00423-023-02858-9.
7
Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma.局部晚期或转移性肝细胞胆管癌的管理
Cancers (Basel). 2023 Feb 3;15(3):988. doi: 10.3390/cancers15030988.
8
Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.肝细胞癌-胆管癌合并症的病理学:最新进展
Cancers (Basel). 2023 Jan 13;15(2):494. doi: 10.3390/cancers15020494.
9
A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.一种新型的肝细胞癌和肝内胆管细胞癌合并的小鼠模型。
J Transl Med. 2022 Dec 9;20(1):579. doi: 10.1186/s12967-022-03791-z.
10
Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.肝细胞-胆管细胞癌:病理学与诊断方法的最新进展
Biomedicines. 2022 Jul 29;10(8):1826. doi: 10.3390/biomedicines10081826.